Navigation Links
NewCardio Joins the Cardiac Safety Research Consortium
Date:1/22/2009

ts are not guarantees of future performance and involve risks and uncertainties that are difficult to predict. Therefore, actual outcomes and results may, and are likely to, differ materially from what is expressed or forecasted in the forward-looking statements due to numerous factors, including the potential risks and uncertainties set forth in Item 1A of our Annual Report on Form 10-K/A (No. 2) for the year ended December 31, 2007 and relate to our business plan, our business strategy, development of our proprietary technology platform and our products, timing of such development, timing and results of clinical trials, level and timing of FDA regulatory clearance or review, market acceptance of our products, protection of our intellectual property, implementation of our strategic, operating and people initiatives, benefits to be derived from personnel and directors, ability to commercialize our products, our assumptions regarding cash flow from operations and cash on-hand, the amount and timing of operating costs and capital expenditures relating to the expansion of our business, operations and infrastructure, implementation of marketing programs, our key agreements and strategic alliances, our ability to obtain additional capital as, and when, needed, and on acceptable terms and general economic conditions specific to our industry, any of which could impact sales, costs and expenses and/or planned strategies and timing. We assume no obligation to, and do not currently intend to, update these forward-looking statements.

To join our email distribution please click this link: http://www.b2i.us/irpass.asp?BzID=1645&to=ea&s=0

    Investor Contact:
    Hayden IR
    Jeff Stanlis
    Partner and Vice President of Communications
    (602) 476-1821
    jeff@haydenir.com


'/>"/>
SOURCE NewCardio, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dorin Panescu Named NewCardios Chief Technical Officer
2. NewCardio Management to Host Conference Call on October 21
3. Glen C. Williams Joins eLearning Sales Team for Simbionix, Heading up Chicago Office
4. Valerie DeFillipo, Reproductive Health and Rights Expert, Joins Abt Associates
5. Dr. Steven L. Zelenkofske Joins Regado Biosciences as Senior Vice President, Clinical and Medical Affairs and Chief Medical Officer
6. David Bagley Joins Histogen as President
7. Biotechnology Veteran Michael Webb Joins Boston-based Investment Bank as Senior Advisor
8. Dr Stephan Rietiker Joins BioCeramic Therapeutics
9. Dr. John Stephen Osika, HIV/AIDS and Infectious Disease Expert, Joins Abt Associates
10. GEN Joins Charles Darwin 2009 Celebration
11. BioLife Solutions Joins Prestigious Biomedical Excellence for Safer Transfusion Collaborative
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... 2015  Neurotech Pharmaceuticals, Inc., announced today the ... Phase 2 clinical trial of NT-503 Encapsulated Cell ... subfoveal choroidal neovascularization secondary to age related macular ... endothelial growth factor (VEGF) receptor protein continuously produced ... landmark proof-of-concept study will evaluate NT-503 ECT as ...
(Date:9/2/2015)... , Sept. 2, 2015 Aytu BioScience, Inc. ... treatments for urological and related conditions, announced today that ... private placement convertible note financing, raising a total of ... totaling $3.175 million. Josh Disbrow ... this private placement are intended to be used to ...
(Date:9/2/2015)... TEL-AVIV, Israel , September 2, 2015 /PRNewswire/ ... BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a ... innovations in ophthalmology and cancer diagnostics, announced today ... treatment of glaucoma will be delivered at the ... of the European Society of Cataract & Refractive ...
(Date:9/2/2015)... , September 2, 2015 ... des Wettbewerbs BeHEARD von 2015 bekanntgeben zu können. ... Rare Genomics Institute. Biovista unterstützt mit ... für die Behandlung anderer Krankheiten als denen, für ... Laffoon und sein Team bei der Wylder ...
Breaking Biology Technology:Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 2Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 3Neurotech Announces First Patient Enrolled in Novel Anti-VEGF Encapsulated Cell Therapy Study 4Aytu BioScience Completes $5.175 Million Private Placement 2Aytu BioScience Completes $5.175 Million Private Placement 3Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 2Presentations to Highlight BioLight's IOPtiMate[TM] System at Upcoming European Ophthalmology Conferences 3Biovista sponsert die Forschung von Wylder Nation Foundation zum Thema Mangel an saurer Sphingomyelinase 2
... 17, 2011 The " Biochips ... Arrays) Trends & Global Forecast (2010-2015) " analyzes ... the major market drivers, restraints, opportunities, and market trends ... Rest of the World. Browse ...
... Researchers from North Carolina State University have found a new ... Growing such nanofiber coatings is important for use in novel ... The technique utilizes a charged chromium grid, and relies on ... which limits their utility. "This is the first ...
... 16, 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: ... from the U.S. Food and Drug Administration (FDA) that ... the priority review of the EYLEA Biologics License Application ... (wet AMD) to November 18, 2011, which is a ...
Cached Biology Technology:MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015 2MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015 3MarketsandMarkets: Global Biochip (DNA Microarrays, Lab-on-Chip, Protein Microarrays, Tissue & Cell Arrays) Market to Reach $5.6 Billion by 2015 4Ions control shape of nanofibers grown on clear substrate 2Ions control shape of nanofibers grown on clear substrate 3Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 2Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 3Regeneron Announces Review of Biologics License Application for EYLEA™ (aflibercept injection) Extended by Three Months by FDA 4
(Date:8/18/2015)... Aug. 18, 2015  Navitas today announced ... to the Submission Content Management webinar scheduled ... non-profit forum. Dedicated to the Implementation of Regulatory ... platform for industry, vendors, health authorities, consultants ... work towards a standard method of implementing ...
(Date:8/17/2015)... , Aug. 17, 2015  NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market and ... sales campaign for Q4 2015. The new marketing campaign ... consisting of Amplitude Marketing Group ( http://amplitudemarketing.com/ ) and ... is a leader in retail driven marketing and brand ...
(Date:8/12/2015)... SPRINGS, Florida , August 12, 2015 ... the pace of mobile payment innovation and advanced biometrics ... to replace the way consumers rely on using their ... ahead with reinventing the future for payment services led ... (NASDAQ: NXTD ), :  Google, Inc. (NASDAQ: ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... at the University of Chicago finds evidence for a ... of loneliness: They create people in their surroundings to ... very efficient way to alleviate ones loneliness, but you ... so, said Nicholas Epley, Assistant Professor of Behavioral Science ...
... French . Researchers at the ... neurological basis of depression in male athletes with persisting ... of Archives of General Psychiatry, has important clinical implications ... cerebral concussion. Depression is one of a ...
... German . Genetically engineered products have become ... future, gene therapy should make it possible to introduce genes ... can address deficiencies to compensate for malfunctions in the body. ... must be introduced into host cells, which is not exactly ...
Cached Biology News:People not always needed to alleviate loneliness 2People not always needed to alleviate loneliness 3MNI researchers locate neurological basis of depression following sports concussion 2Cells get sprayed 2
... Clone/PAD: ZMD.473. Immunogen: Synthetic ... of the mouse junctophilin-2. Specificity: ... Reactivity: Mouse (positive controls: mouse skeletal ... tissues). Applications: Western blotting Immunohistochemistry(froz) ...
TGF-beta 2 MAb (Clone 8607)...
UCP1/2/3 (FL-307)...
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
Biology Products: